Table 1.
Demographic and clinical data of the patients of the intention-to-treat population at the time of randomization (n = 434). Data are separately shown for the two groups of randomization and reported as mean (±SD) or absolute (n) and relative frequency (%). BMI: Body Mass Index; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; CV: cardiovascular; SBP: systolic blood pressure; DBP: diastolic blood pressure.
| Zofenopril 30–60 mg + HCTZ 12.5 mg | Irbesartan 150–300 mg + HCTZ 12.5 mg | p value | |
|---|---|---|---|
| (n = 213) | (n = 221) | ||
| Age (years, mean ± SD) | 56 ± 11 | 56 ± 11 | 0.926 |
| Males (n, %) | 124 (58) | 120 (54) | 0.411 |
| BMI (kg/m2, mean ± SD) | 27 ± 3 | 27 ± 3 | 0.415 |
| Waist circumference (cm, mean ± SD) | 98 ± 10 | 98 ± 10 | 0.674 |
| Age at first diagnosis of hypertension (years, mean ± SD) | 49 ± 11 | 50 ± 11 | 0.850 |
| Concomitant diseases (n, %) | 140 (66) | 133 (60) | 0.232 |
| Alcohol drinking (n, %) | 62 (29) | 74 (33) | 0.326 |
| Cigarette smoking (n, %) | 61 (29) | 65 (29) | 0.859 |
| Diabetes (n, %) | 23 (11) | 23 (10) | 0.895 |
| Elevated total cholesterol (n, %) | 153 (72) | 165 (75) | 0.506 |
| Elevated LDL cholesterol (n, %) | 147 (69) | 156 (71) | 0.721 |
| Low HDL cholesterol (n, %) | 51 (24) | 57 (26) | 0.656 |
| Abdominal obesity (n, %) | 181 (85) | 187 (85) | 0.917 |
| Family history of premature CV disease (n, %) | 35 (16) | 32 (15) | 0.574 |
| High CV risk (n, %) | 197 (93) | 204 (92) | 0.943 |
| Sitting office SBP (mmHg) | 150 ± 11 | 151 ± 11 | 0.335 |
| Sitting office DBP (mmHg) | 93 ± 7 | 93 ± 7 | 0.366 |